Advertisement

Alkermes Inc. has announced positive results from an early stage clinical trial testing the efficacy of its drug candidate ALKS 33 in treating cocaine addiction.

The company also said it has been awarded a grant of up to $2.4 million from the National Institute on Drug Abuse Grants to speed up development of the potential therapy.

SOURCE

Advertisement
Advertisement